Literature DB >> 21960716

Reduced thymic output is a major mechanism of immune reconstitution failure in HIV-infected patients after long-term antiretroviral therapy.

Taisheng Li1, Ning Wu, Yi Dai, Zhifeng Qiu, Yang Han, Jing Xie, Ting Zhu, Yanling Li.   

Abstract

BACKGROUND: Approximately 20% of human immunodeficiency virus type 1 (HIV-1)--infected adults do not normalize their CD4(+) T lymphocytes after long-term effective highly active antiretroviral therapy (HAART). The mechanistic basis for this failure is unclear.
METHODS: Seventy-four patients were followed up regularly for 3-7 years. Patients with undetectable plasma viral load (<50 copies/mL) for over 12 months were further classified into 2 groups: (1) immunological nonresponders, whose CD4(+) T-cell count was < 200/μL or <20% compared with baseline; and (2) immunological responders, whose CD4(+) T-cell count was > 300/μL or >30% compared with baseline.
RESULTS: Compared with 17 immunological responders, 13 immunological nonresponders had a lower magnitude of naive CD4(+) T-cell increase, a lower percentage of recent thymic immigrants (CD31(+)%), and a higher percentage of activated CD8(+) T cells. Furthermore, unlike CD4(+) T cells, which increased along with the decrease of viral load, the percentage of recent thymic immigrants (CD31(+)%) had little change in the majority of patients. These data were fit into a mathematical model, , from which we deduced that the initial rate of CD4(+) T-cell restoration is associated significantly with the percentage of recent thymic immigrants (CD31(+)%).
CONCLUSIONS: Our data indicate that the failure to restore CD4(+) T-cell count following HAART was associated primarily with a defect in recent thymic immigrants, which suggests the existence of thymus exhaustion.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21960716     DOI: 10.1093/cid/cir552

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  39 in total

1.  Thymic Function Failure Is Associated With Human Immunodeficiency Virus Disease Progression.

Authors:  Sara Ferrando-Martinez; Rebeca S De Pablo-Bernal; Marta De Luna-Romero; Santiago J De Ory; Miguel Genebat; Yolanda M Pacheco; Francisco J Parras; Marta Montero; Jose Ramón Blanco; Felix Gutierrez; Jesus Santos; Francisco Vidal; Richard A Koup; María Ángeles Muñoz-Fernández; Manuel Leal; Ezequiel Ruiz-Mateos
Journal:  Clin Infect Dis       Date:  2017-05-01       Impact factor: 9.079

2.  Recent Thymus Emigrant CD4+ T Cells Predict HIV Disease Progression in Patients With Perinatally Acquired HIV.

Authors:  Ramia Zakhour; Dat Q Tran; Guenet Degaffe; Cynthia S Bell; Elizabeth Donnachie; Weihe Zhang; Norma Pérez; Laura J Benjamins; Gabriela Del Bianco; Gilhen Rodriguez; James R Murphy; Gloria P Heresi
Journal:  Clin Infect Dis       Date:  2016-02-21       Impact factor: 9.079

3.  Brief Report: Role of Thymic Reconstitution in the Outcome of AIDS-Related PML.

Authors:  Spyridon G Chalkias; Sarah Gheuens; Evelyn Bord; Stephanie Batson; Igor J Koralnik
Journal:  J Acquir Immune Defic Syndr       Date:  2015-12-01       Impact factor: 3.731

4.  Role of intestinal myofibroblasts in HIV-associated intestinal collagen deposition and immune reconstitution following combination antiretroviral therapy.

Authors:  David M Asmuth; Irina V Pinchuk; Jian Wu; Gracie Vargas; Xiaoli Chen; Surinder Mann; Anthony Albanese; Zhong-Min Ma; Ramez Saroufeem; Gregory P Melcher; Paolo Troia-Cancio; Natalie J Torok; Christopher J Miller; Don W Powell
Journal:  AIDS       Date:  2015-05-15       Impact factor: 4.177

5.  The effects of prebiotics on microbial dysbiosis, butyrate production and immunity in HIV-infected subjects.

Authors:  S Serrano-Villar; J F Vázquez-Castellanos; A Vallejo; A Latorre; T Sainz; S Ferrando-Martínez; D Rojo; J Martínez-Botas; J Del Romero; N Madrid; M Leal; J I Mosele; M J Motilva; C Barbas; M Ferrer; A Moya; S Moreno; M J Gosalbes; V Estrada
Journal:  Mucosal Immunol       Date:  2016-12-21       Impact factor: 7.313

6.  Immune Reconstitution but Persistent Activation After 48 Weeks of Antiretroviral Therapy in Youth With Pre-Therapy CD4 >350 in ATN 061.

Authors:  Bret J Rudy; Bill G Kapogiannis; Carol Worrell; Kathleen Squires; James Bethel; Su Li; Craig M Wilson; Allison Agwu; Patricia Emmanuel; Georgine Price; Stephanie Hudey; Maureen M Goodenow; John W Sleasman
Journal:  J Acquir Immune Defic Syndr       Date:  2015-05-01       Impact factor: 3.731

7.  CD31 Expression on CD4+ Cells: A Simple Method for Quantitation of Recent Thymus Emigrant CD4 Cells.

Authors:  Ramia Zakhour; Dat Q Tran; Gloria P Heresi; Guenet Degaffe; Cynthia S Bell; Elizabeth Donnachie; Weihe Zhang; Norma Pérez; Laura J Benjamins; Gabriela Del Bianco; Gilhen Rodriguez; James R Murphy
Journal:  Am J Trop Med Hyg       Date:  2016-08-15       Impact factor: 2.345

8.  Responsiveness to IL-7 but not to IFN-α is diminished in CD4+ T cells from treated HIV infected patients who experience poor CD4+ T-cell recovery.

Authors:  Thao P Nguyen; Supriya Shukla; Robert Asaad; Michael L Freeman; Michael M Lederman; Clifford V Harding; Scott F Sieg
Journal:  AIDS       Date:  2016-08-24       Impact factor: 4.177

9.  Association between discordant immunological response to highly active anti-retroviral therapy, regulatory T cell percentage, immune cell activation and very low-level viraemia in HIV-infected patients.

Authors:  J Saison; T Ferry; J Demaret; D Maucort Boulch; F Venet; T Perpoint; F Ader; V Icard; C Chidiac; G Monneret
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

10.  Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy.

Authors:  Eugènia Negredo; Marta Massanella; Maria C Puertas; Maria J Buzón; Jordi Puig; Núria Pérez-Alvárez; Josué Pérez-Santiago; Anna Bonjoch; José Moltó; Antoni Jou; Patricia Echeverría; Josep M Llibre; Javier Martínez-Picado; Bonaventura Clotet; Julià Blanco
Journal:  J Antimicrob Chemother       Date:  2013-05-14       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.